LAS VEGAS, Dec. 12, 2017 -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), today announced that it will be exhibiting at the 25th Annual World Congress on Anti-Aging Medicine, held on December 14-16th, 2017 at the Venetian/Palazzo Resort in Las Vegas, Nevada. This will be the Company’s fourth year exhibiting at this cutting-edge practitioner conference and expo.
The American Academy of Anti-Aging (A4M) is a non-profit organization educating healthcare professionals and practitioners, scientists, and members of the public on biomedical sciences, breakthrough technologies, and medical protocols through their advanced education entity: Metabolic Medical Institute (MMI). A4M has acquired a membership of over 26,000 members, which includes physicians, nurses, scientists, researchers, governmental officials, and members of the general public that represent over 120 nations.
Hosting up to 5,000 physicians and healthcare practitioners, this year’s Annual World Congress marks a quarter of a century since A4M began its original mission: to build awareness and deliver innovative, cutting-edge scientific education focused on longevity, and prolonging the human lifespan. 2017 marks the first year A4M has dedicated a specific education track related to cannabis as a modality. CV Sciences encourages attendees to attend these lectures to learn more about how cannabis products may influence positive health outcomes.
“This year is particularly exciting given A4M’s focus on providing an education track related to cannabis as an integrative, functional and nutritional modality. This will be an opportunity for CV Sciences to showcase our leadership efforts as the driving force of the hemp-derived CBD category for the healthcare practitioners market,” states Stuart Tomc, VP of Human Nutrition at CV Sciences. “The A4M Annual World Congress brings together renowned speakers, keynotes, and impressive faculty panels who assist attendees in implementing and integrating new therapies into practice, which fits the current demand for phytocannabinoids like CBD. Practitioners continue to seek out reliable information on the current benefits of hemp-derived CBD, and we are looking forward to another year educating forward-thinking professionals on breakthrough therapies for their patients.”
VISIT BOOTH 4061: CV Sciences invites attendees to visit Booth 4061 to learn more about their industry-dominating brand of hemp-derived cannabidiol (CBD) oil finished products, PlusCBD Oil™, from CV Sciences’ staff and scientific advisors attending the show. The Company will additionally feature its brand of practitioner-exclusive products available only to healthcare providers nationwide. Also, CV Sciences will be offering exclusive trade show discounts and show specials to practitioners attending the show.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT:
Robert Haag, Managing Director
IRTH Communications
[email protected]
866-976-4784


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Anta Sports Expands Global Footprint With Strategic Puma Stake
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Washington Post Publisher Will Lewis Steps Down After Layoffs
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



